RxDoctor Payments Data

Nancy Hammond, MD

Neurology · Kansas City, KSNPI 1558391862

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,750 of the $4,673 with a category attached, or 80.3%. Livanova USA, Inc. accounts for 80.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $3,803 and has fallen 95.6% since, to $167 in 2025.

$4,673in general payments, 2019–2025

Across 41 payments — averaging $113.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$4K
  • Eisai Inc.$283
  • SK Life Science, Inc.$211
  • Supernus Pharmaceuticals, Inc.$202
  • UCB, Inc.$87
  • Novartis$40
  • plus $79 from 4 others
$18,425in research payments, 2019–2025

Across 13 payments — averaging $1417.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sunovion Pharmaceuticals Inc.$18K

What the payments were for

  • Speaking & faculty fees$3,75080%
  • Food & beverage$92320%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,673 in reported general payments places this provider in the 70th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$38,986
Medicare patients
309
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)55$477,842
BriviactBrivaracetam39$75,925
LamictalLamotrigine11$40,586
VimpatLacosamide15$37,713
KeppraLevetiracetam19$28,545
AptiomEslicarbazepine Acetate11$27,984
Tegretol XrCarbamazepine39$26,874
Lacosamide144$23,140
Clobazam80$19,445
Nurtec OdtRimegepant Sulfate11$17,858
NayzilamMidazolam27$17,817
Aimovig AutoinjectorErenumab-Aooe14$14,956
Levetiracetam287$14,862
Emgality PenGalcanezumab-Gnlm15$10,663
ZoloftSertraline Hcl12$10,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$87$131,45581 claims
Upsher-smith Laboratories LLCTopiramate$25$2,221112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 neurology providers in Kansas.

Other neurology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →